BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid

Current Alzheimer Research

Volumn 10, Issue 7, 2013, Pages 671-678

  Barão, Soraia ^a,b   Zhou, Lujia ^a,b   Adamczuk, Katarzyna ^c   Vanhoutvin, Tine ^a,b   van Leuven, Fred ^d   Demedts, David ^d   Vijverman, Anne Catherine ^b   Bossuyt, Xavier ^c   Vandenberghe, Rik ^b,c   De Strooper, Bart ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; BACE1; Biomarker; Human CSF; Neurodegeneration; Sandwich ELISA

Indexed keywords

BETA SECRETASE 1; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MINI MENTAL STATE EXAMINATION; MOUSE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BIOLOGICAL MARKERS; FEMALE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; NERVOUS SYSTEM DISEASES; PHOSPHORYLATION; PROTEIN STRUCTURE, SECONDARY; SINGLE-BLIND METHOD; TAU PROTEINS;

EID: 84888225102     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990138     Document Type: Article

References (41)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12): 4245-4249 (1985).
2. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67(3): 446-452 (2006).
3. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129(Pt 11): 3035-3041 (2006).
4. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4): 403-413 (2009).
5. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30(12): 1895-1901 (2009).
6. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med 367(9): 795-804 (2012).
7. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735-741 (1999).
8. Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 14(3): 379-383 (2004).
9. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129(Pt 11): 2823-2839 (2006).
10. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90(2): 465-494 (2010).
11. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta- secretase from human brain. Nature 402(6761): 537-540 (1999).
12. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H. Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem 277(7): 4687-4693 (2002)
13. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29(41): 12787-12794 (2009).
14. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290(5489): 150-153 (2000).
15. Hong L, Tang J. Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. Biochemistry 43(16): 4689-4695 (2004).
16. Hong L, Turner RT, 3rd, Koelsch G, Shin D, Ghosh AK, Tang J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry 41(36): 10963-10967 (2002).
17. Turner RT, 3rd, Hong L, Koelsch G, Ghosh AK, Tang J. Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). Biochemistry 44(1): 105-112 (2005).
18. Zhou L, Chavez-Gutierrez L, Bockstael K, Sannerud R, Annaert W, May PC, et al. Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem 286(10): 8677-8687 (2011).
19. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51(6): 783-786 (2002).
20. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59(9): 1381-1399 (2002).
21. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9(1): 3-4 (2003).
22. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101(10): 3632-3637 (2004).
23. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, et al. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci Res 54(1): 24-29 (2006).
24. Murayama KS, Kametani F, Araki W. Extracellular release of BACE1 holoproteins from human neuronal cells. Biochem Biophys Res Commun 338(2): 800-807 (2005).
25. Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 52(6): 1168-1174 (2006).
26. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, et al. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin Biochem 41(12): 986-996 (2008).
27. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4): 652-656 (2003).
28. Hampel H, Shen Y. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scand J Clin Lab Invest 69(1): 8-12 (2009).
29. Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 55(6): 898-899 (2004).
30. Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology 67(4): 710-712 (2006).
31. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64(6): 718-726 (2007).
32. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65(8): 1102-1107 (2008).
33. Mattsson N, Axelsson M, Haghighi S, Malmestrom C, Wu G, Anckarsater R, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler 15(4): 448-454 (2009).
34. Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 20(1): 253-260 (2010).
35. Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel SJ, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 131(Pt 5): 1252-1258 (2008).
36. Gonzales A, Decourt B, Walker A, Condjella R, Nural H, Sabbagh MN. Development of a specific ELISA to measure BACE1 levels in human tissues. J Neurosci Methods 202(1): 70-76 (2011).
37. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280(35): 30797-30806 (2005).
38. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16(11): 460-465 (1993).
39. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26(3): 231-245 (1995).
40. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2(3-4): 199-206 (2000).
41. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 61(3): 235-242 (2003).